|
|
|
|
|
Penciclovir
drug data and news
Penciclovir drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Penciclovir | ||
| Brand Names/Synonyms | Denavir; PE2; Penciclovir; Penciclovir [Usan:Ban:Inn]; Penciclovirum [Inn-Latin] | ||
| Indication | Used to treat recurrent cold sores on the lips and face. | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Penciclovir is the active metabolite of the oral product famciclovir. The more favorable results observed with topical penciclovir versus topical acyclovir for the treatment of herpes labialis may be due to the longer intracellular half-life of penciclovir in HSV-infected cells. | ||
| Mechanism Of Action | Penciclovir has in vitro activity against herpes simplex virus types 1 (HSV-1) and 2 (HSV-2). In cells infected with HSV-1 or HSV-2, viral thymidine kinase phosphorylates penciclovir to a monophosphate form. The monophosphate form of the drug is then converted to penciclovir triphosphate by cellular kinases. The intracellular triphosphate of penciclovir is retained in vitro inside HSV-infected cells for 10-20 hours, compared with 0.7-1 hour for acyclovir. in vitro studies show that penciclovir triphosphate selectively inhibits viral DNA polymerase by competing with deoxyguanosine triphosphate. Inhibition of DNA synthesis of virus-infected cells inhibits viral replication. In cells not infected with HSV, DNA synthesis is unaltered. Resistant mutants of HSV can occur from qualitative changes in viral thymidine kinase or DNA polymerase. The most commonly encountered acyclovir-resistant mutants that are deficient in viral thymidine kinase are also resistant to penciclovir. | ||
| Penciclovir News (When available) |
Recent Developments in the Treatment of Cutaneous Viral Infections Apr 20, 2006 Barrier Therapeutics Announces First Quarter 2006 Financial ... May 2, 2006 | ||
| Dosage Forms | Topical cream | ||
| Drug_Category | Antivirals; ATC:D06BB06; ATC:J05AB13 | ||
| Absorption | Measurable penciclovir concentrations were not detected in plasma or urine of healthy male volunteers (n= 12) following single or repeat application of the 1% cream at a dose of 180 mg penciclovir daily. | ||
| Interactions |
Interactions for Penciclovir: No information provided. | ||
| Toxicity | Headache, abdominal pain, increased serum lipase, nausea, dyspepsia, dizziness, and hyperbilirubinemia. | ||
| Organisms Affected | Herpes simplex virus | ||
| Chemical IUPAC Name | 2-amino-9-[4-hydroxy-3-(hydroxymethyl)butyl]-3,9-dihydropurin-6-one | ||
| Chemical Formula | C10H15N5O3 | ||
| Molecular Weight | 253.258 g/mol | ||
| Smiles String | C1=NC2=C(N1CCC(CO)CO)NC(=NC2=O)N | ||
| Melting Point | 275-277 °C[an error occurred while processing this directive] |